Two posters presented at the CHEST Annual Meeting 2023 showed how real-world exacerbation rates in asthma and chronic obstructive pulmonary disease (COPD) dropped after patients started using a single ...
Mepolizumab significantly reduces exacerbations in patients with asthma and concurrent chronic obstructive pulmonary disease (COPD), with a 55% reduction in COPD exacerbations post initiation. A ...
Patients with chronic obstructive pulmonary disease (COPD) who have higher levels of HbA1c are at increased risk for hospital admission for acute exacerbations. Patients with chronic obstructive ...
Treatment with once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) triple therapy appears to be more efficacious in reducing ...
Please provide your email address to receive an email when new articles are posted on . The rate of exacerbation was 46.8% in the group using metformin and 63% in the group not using metformin. The ...
Artificial intelligence (AI) and natural language processing tools can build an algorithm that identifies patients with chronic obstructive pulmonary disease (COPD) at risk for exacerbations, ...
New research shows that individual exacerbations in chronic obstructive lung disease (COPD) themselves increase the likelihood of repeat exacerbations, even after five days of full, asymptomatic ...
Credit: Shutterstock. Patients with chronic obstructive pulmonary disease (COPD) who have higher levels of HbA1c are at increased risk for hospital admission for acute exacerbations. This article is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results